EILEEN LIMCHOA: Open Payments
NPI 1225640030 · WYANDOTTE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$470 in 23 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $123 · 2025 $470
Food & beverage: $470
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 8 | $154 |
| ACADIA Pharmaceuticals Inc | 4 | $91 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| ABBVIE INC. | 2 | $31 |
| SK Life Science, Inc. | 1 | $30 |
| Janssen Biotech, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| JAZZ PHARMACEUTICALS INC. | 1 | $16 |
Products named: NUPLAZID, Fintepla, Briviact, KEVEYIS, PONVORY, Rystiggo, Nayzilam, VYEPTI.
Industry payments across MI — which companies pay providers there.
